Movement Alert|Revolution Medicines, Inc. Falls 4.13% in Regular Trading, Post-Earnings Valuation Digestion Pressure Persists

Market Focus
11/11

On November 11, Revolution Medicines, Inc. fell 4.13% in Regular Trading, trading at $184.891 per share, with turnover of $68.6961 million.

The clearest catalyst in recent market coverage is continued post-earnings valuation digestion following the company’s third-quarter report and a wave of analyst target-price increases.

Background shows Revolution Medicines, Inc. reported quarterly EPS of $(1.90), better than the $(2.42) consensus estimate, while revenue was $197.559 million versus a much lower market estimate that was flagged as not fully comparable. After the report, several firms raised targets, including RBC to $321, Evercore to $340, and JP Morgan to $289, reflecting confidence in the commercial outlook for Rasonque after its approval. Even so, recent coverage indicated that earlier optimism had already been substantially priced in, leaving the shares under pressure as investors reassessed valuation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10